Page 51 - CIBEREHD2016-ENG

Most relevant scientific articles
• Abraldes JG, Villanueva C, Aracil C, Turnes J, Hernandez-Guerra M, Genesca J et al. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis.Gastroenterology. 2016;150(5).
• Calderone V, Gallego J, Fernandez-Miranda G, Garcia-Pras E, Maillo C, Berzigotti A et al. Sequential Functions of CPEB1 and CPEB4 Regulate Pathologic Expression of VEGF and Angiogenesis in Chronic Liver Disease.Gastroenterology. 2016;150(4).
• Berzigotti A, Albillos A, Villanueva C, Genescá J, Ardevol A, Augustín S et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The sportdiet study.Hepatology (Baltimore, Md.). 2016.
• Noronha Ferreira C., Seijo S., Plessier A., Silva-Junior G., Turon F., Rautou P.-E. et al. Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. Hepatology. 2016;63(5):1640-1650.
• Escorsell A., Pavel O., Cardenas A., Morillas R., Llop E., Villanueva C. et al. Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial. Hepatology. 2016;63(6):1957-1967.
Hightlights
PUBLICATIONS
The group has published a total of 32 publications (19 Originals, 6 Reviews, 2 Editorials, 2 Letters and 3 Clinical Trials), and also 2 Clinical Guidelines. Of these publications, 18 were collaborative, 21 were in magazines of the first decile and 28 in magazines of the first quartile.
PROJECTS
The group has 12 active competitive projects, in charge of the following IP:
• Bosch J: a. Contrast-enhanced uLtrasound for livEr-disease eValuation: development and validation of a
novel E-Health-software for Risk-stratification (CLEVER). 612273. European Commission. b. Understanding obesity (Ob), metabolic syndrome (MetS), type 2 diabetes (T2DM) and fatty liver disease (FL): a multidisciplinary approach. PIE14/00031.With 4 CIBER group participating.. c. Hepatic hemodynamics and portal hypertension in cirrhosis. Advances in pathophysiology and treatment (Clinical and experimental studies). ISCIII. PI13/00341.
• García Pagán JC: a. Targeting endothelial dysfunction in highly prevalent diseases: characterization and validation of prognostic biomarkers and identification of potential therapeutic strategies. PIE15/00027. b. Multivessel, randomized prospective study of the effect of Rivaroxaban on the survival and development of portal hypertension complications in patients with cirrhosis. ISCIII. ICI14/00133. c. Molecular mechanisms involved in structural and functional alterations in the liver in the progression to cirrhosis with portal hypertension. SAF2013-44723-R.
• Fernández M: a. Molecular regulation of the interaction between obesity and chronic liver disease. BES2015-071399. b. Molecular and cellular mechanisms involved in the interaction between obesity and chronic liver disease: role and therapeutic potential of angiogenesis and CPEB proteins. SAF2014-55473-R
• Gracia-Sancho J: a. The hepatic sinusoid in old age: characterization of pathophysiological cellular mechanisms for the development of new therapeutic strategies. FIS PI14/00029. b. BioLiver: Deconstruction applied to Hepatology. MINECO. Explora BIO2014-61377-EXP.
• Hernández-Gea V: Role of autophagy in the modulation of endothelial dysfunction and fibrosis: characterization of a new therapeutic target for the development of new antifibrotic treatments. FIS PI14/00182.
research Groups 51
• Escorsell A: Efficacy of intrahepatic portosystemic shunt (TIPS) in the treatment of acute gastric variceal hemorrhage: a randomized controlled trial versus conventional treatment. FIS PI14/00392.
EHD